Cargando…

Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients

INTRODUCTION: The soluble receptor of urokinase plasminogen activator (suPAR) is an innate immunity/inflammation biomarker predicting cardiovascular (CV) and non-CV events in various conditions, including type 2 diabetic patients on dialysis. However, the relationship between suPAR and clinical outc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torino, Claudia, Pizzini, Patrizia, Cutrupi, Sebastiano, Postorino, Maurizio, Tripepi, Giovanni, Mallamaci, Francesca, Reiser, Jochen, Zoccali, Carmine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127402/ https://www.ncbi.nlm.nih.gov/pubmed/30197976 http://dx.doi.org/10.1016/j.ekir.2018.05.004

Ejemplares similares

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022)

Vitamin D and methylarginines in chronic kidney disease (CKD)
por: Torino, Claudia, et al.
Publicado: (2017)

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency
por: Höybye, Charlotte, et al.
Publicado: (2019)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
por: Özdirik, Burcin, et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
por: Rasmussen, Line Jee Hartmann, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases
por: Manfredi, Mariangela, et al.
Publicado: (2023)

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
por: Rovina, Nikoletta, et al.
Publicado: (2020)

Increased Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in Plasma of Suicide Attempters
por: Ventorp, Filip, et al.
Publicado: (2015)

Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience
por: Infantino, Maria, et al.
Publicado: (2022)

Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients
por: Torino, Claudia, et al.
Publicado: (2017)

The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders
por: Vasarhelyi, Barna, et al.
Publicado: (2016)

Evaluation of soluble urokinase-type plasminogen activator receptor (suPAR) quick test for triage in the emergency department
por: Kumar, Pratyush, et al.
Publicado: (2019)

Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis
por: Vassiliou, Alice G., et al.
Publicado: (2022)

Relationship Between Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Disease Outcome in Adult-Onset Asthma
por: Niemelä, Taito, et al.
Publicado: (2022)

Sex Differences in Circulating Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease
por: Mehta, Anurag, et al.
Publicado: (2020)

Relationship of Circulating Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels to Disease Control in Asthma and Asthmatic Pregnancy
por: Ivancsó, István, et al.
Publicado: (2013)

Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
por: Lee, Jiwon M., et al.
Publicado: (2019)

Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
por: Emrah, Acar, et al.
Publicado: (2016)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19
por: Enocsson, Helena, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Emergency Department (Ed): A Tool for the Assessment of Elderly Patients
por: Holstein, Ria M., et al.
Publicado: (2022)

Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study
por: Spoto, Belinda, et al.
Publicado: (2019)

Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases
por: Loosen, Sven H., et al.
Publicado: (2018)

The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine
por: Scharrenberg, Jan Simon, et al.
Publicado: (2019)

Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study
por: Schulz, Christina-Alexandra, et al.
Publicado: (2016)

Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method
por: Winnicki, Wolfgang, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit
por: Reisinger, Alexander C., et al.
Publicado: (2021)

Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients
por: Jehn, Ulrich, et al.
Publicado: (2021)

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Biomarker Associated with Left Ventricular Hypertrophy in the Elderly, Specifically in Women
por: Wlazeł, Rafał Nikodem, et al.
Publicado: (2023)

Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma
por: Kotsiou, Ourania S., et al.
Publicado: (2022)

Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy
por: Schultz, Martin, et al.
Publicado: (2019)

High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma
por: Loosen, Sven H, et al.
Publicado: (2019)

The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Context of Aneurysmal Subarachnoid Hemorrhage (aSAH)—A Prospective Observational Study
por: Schmidt, Tobias P., et al.
Publicado: (2022)

suPAR: An Inflammatory Mediator for Kidneys
por: Sudhini, Yashwanth Reddy, et al.
Publicado: (2022)

Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus
por: Guthoff, Martina, et al.
Publicado: (2017)

The Relationship Between Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Treatment Response in Patients With Glomerulonephritis: A Single-Center Experience
por: İşsever, Kubilay, et al.
Publicado: (2023)

Reassessing the Reassessment of suPAR in Glomerular Disease
por: Meijers, Björn K. I., et al.
Publicado: (2015)

Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa
por: Lawn, Stephen D, et al.
Publicado: (2007)

Point-of-care prognostication in moderate Covid-19: Analytical validation and prognostic accuracy of a soluble urokinase plasminogen activator receptor (suPAR) rapid test
por: Chandna, Arjun, et al.
Publicado: (2023)

Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study
por: Rasmussen, Line Jee Hartmann, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rcga2mhdkg2v7bna2sf7pjv1vp